Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
It is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, which means it acts on two different hormonal pathways to help regulate blood sugar levels and confer additional metabolic benefits, including weight loss
No serious adverse events were reported in the early trials, and the safety profile has remained consistent across the larger Phase 3 programs
Retatrutide is an investigational once-weekly injectable triple receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors to reduce appetite, enhance insulin secretion, and potentially increase energy expenditure
Their capacity to encapsulate and deliver both hydrophilic and lipophilic drugs concurrently, along with their simple design and preparation, biocompatibility, and biodegradability, has facilitated their use as drug delivery carriers in a range of therapies, including Wound Healing, to accurately deliver at the target site (Wilhelm Romero et al., 2021)
